Abstract: An external bed type double-fluidized bed system for preventing boiler contamination includes a fluidized bed combustion furnace, a cyclone separator, a coal ash distributor and a fluidized bed pyrolysis furnace. The fluidized bed combustion furnace is connected with the coal ash distributor, the coal ash distributor is connected with the coal ash inlet on a side wall of the fluidized bed combustion furnace through a return feeder with which the coal ash outlet of the fluidized bed pyrolysis furnace is also connected through an external bed, and the return feeder is connected with the fluidized bed combustion furnace. A fuel coal is pyrolyzed in the fluidized bed pyrolysis furnace at a temperature to volatize alkali chlorides into a pyrolysis gas, thereby reducing the content of the alkali chlorides contained in the coal in the fluidized bed combustion furnace and relieving the contamination to a convective heat-absorbing surface.

Abstract: The present invention discloses esters of 4,9-dihydroxy-naphtho[2,3-b]furans and methods of making and using the same. The present invention also discloses conversion of the esters into therapeutically active 4,9-dihydroxy-naphtho[2,3-b]furans in vivo. The present invention furthermore discloses pharmaceutical compositions comprising the esters of 4,9-dihydroxy-naphtho[2,3-b]furans for the treatment of various indications including proliferative diseases.

Abstract: Disclosed is a method for preparing aqueous nanoparticle suspensions of derivatives of 4,9-dihydroxy-naphtho[2,3-b]furan aliphatic acid esters. The compositions and the uses of the aqueous nanoparticle suspensions prepared according to the method as described herein are also disclosed.

Abstract: The present invention discloses novel naphtho[2,3-b]furan-4,9-diones and naphtho[2,3-b]thiophene-4,9-diones and methods of making and using the same. The present invention also discloses pharmaceutical compositions comprising novel naphtho[2,3-b]furan-4,9-dione or naphtho[2,3-b]thiophene-4,9-diones for the treatment of various indications including proliferative diseases.

Abstract: The present invention discloses esters of 4,9-dihydroxy-naphtho[2,3-b]furans and methods of making and using the same. The present invention also discloses conversion of the esters into therapeutically active 4,9-dihydroxy-naphtho[2,3-b]furans in vivo. The present invention furthermore discloses pharmaceutical compositions comprising the esters of 4,9-dihydroxy-naphtho[2,3-b]furans for the treatment of various indications including proliferative diseases.

Abstract: The present disclosure discloses a method, an apparatus, and a system for transmitting and displaying offline data. When communication application software on a client terminal is under an offline state, a background service corresponding to the communication application software at the client terminal is started so that the client terminal establishes a communication connection between the client terminal and a message server via the background service. The client terminal receives offline data from the message server via the background service. The background service also analyzes the offline data to generate a prompt message for displaying, and displays the prompt message at a pre-determined display area. The present techniques enable a user to obtain updated messages in real-time and improve an efficiency of the user for acquiring data and user experiences.

Abstract: The present invention discloses novel naphtho[2,3-b]furan-4,9-diones and naphtho[2,3-b]thiophene-4,9-diones and methods of making and using the same. The present invention also discloses pharmaceutical compositions comprising novel naphtho[2,3-b]furan-4,9-dione or naphtho[2,3-b]thiophene-4,9-diones for the treatment of various indications including proliferative diseases.